Suppr超能文献

一项校准细小病毒B19抗体第二国际标准的合作研究报告。

Report of a collaborative study to calibrate the Second International Standard for parvovirus B19 antibody.

作者信息

Ferguson Morag, Heath Alan

机构信息

Division of Virology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Herts EN6 3 QG, UK.

出版信息

Biologicals. 2004 Dec;32(4):207-12. doi: 10.1016/j.biologicals.2004.09.004.

Abstract

A collaborative study was undertaken to assess the suitability of a replacement for the First International Standard for parvovirus B19 IgG, human serum and to calibrate it in IU. The proposed standard, which is a pool of sera from 16 US blood donors, was assayed along with the First International Standard, a coded duplicate of the proposed standard and a plasma sample from a single blood donor. Nine laboratories from eight countries participated in the studies and five different assay kits were used. Two kits contained VP1+VP2, one kit contained VP1 only and two kits, one of which was used by five participants contained VP2 only. Differences in detection of the proposed standard and the individual plasma were observed with assay kits containing different antigens, VP1, VP2 or VP1+VP2. However, since VP1 is a minor capsid protein and on its own does not assemble into virus like particles and the dominant response in individuals appears to be against VP2, it was considered reasonable to utilize only the data from kits containing VP2 antigen for the calibration of the proposed standard. The results of this study demonstrated that the proposed standard coded 01/602 was suitable to serve as the replacement International Standard for parvovirus B19, serum IgG, and this preparation was established as the Second International Standard for parvovirus B19 antibody, plasma human, with an assigned unitage of 77 IU per ampoule by the Expert Committee on Biological Standardisation of the World Health Organisation in February 2003.

摘要

开展了一项合作研究,以评估用一种替代物取代细小病毒B19 IgG第一国际标准品(人血清)的适用性,并以国际单位(IU)对其进行校准。拟议标准品是来自16名美国献血者的血清池,与第一国际标准品、拟议标准品的一个编码复制品以及一名献血者的血浆样本一起进行了检测。来自八个国家的九个实验室参与了这些研究,并使用了五种不同的检测试剂盒。两种试剂盒含有VP1 + VP2,一种试剂盒仅含有VP1,两种试剂盒(其中一种被五名参与者使用)仅含有VP2。使用含有不同抗原(VP1、VP2或VP1 + VP2)的检测试剂盒时,观察到拟议标准品和个体血浆检测结果存在差异。然而,由于VP1是一种次要的衣壳蛋白,其自身不能组装成病毒样颗粒,而且个体中的主要反应似乎是针对VP2的,因此认为仅利用含有VP2抗原的试剂盒的数据来校准拟议标准品是合理的。这项研究的结果表明,编码为01/602的拟议标准品适合用作细小病毒B19血清IgG的替代国际标准品,并且该制剂于2003年2月被世界卫生组织生物标准化专家委员会确立为细小病毒B19抗体人血浆第二国际标准品,每安瓿指定单位效价为77 IU。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验